Managing diabetic dyslipidaemia-beyond LDL-C:HDL-C and triglycerides

Atherosclerosis Supplements

Volumn 7, Issue 4, 2006, Pages 17-21

  Barter, Philip ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

HDL C; LDL C; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY RISK; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; METABOLIC SYNDROME X; PPAR ALPHA; RISK; RISK FACTORS; TRIGLYCERIDES;

EID: 33746238830     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2006.05.003     Document Type: Article

References (20)

1. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62 (1977) 7-14
2. Assmann G., and Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 70 (1992) 733-737
3. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85 (1992) 37-45
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
5. Taskinen M.R. LDL-cholesterol, HDL-cholesterol or triglycerides-which is the culprit?. Diabetes Res Clin Pract 61 Suppl. 1 (2003) S19-S26
6. Barter P.J., Baker P.W., and Rye K.-A. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 13 (2002) 285-288
7. Pedersen, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97 (1998) 1453-1460
8. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365-374.
9. Sacks F.M., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. Circulation 102 (2000) 1893-1900
10. West of Scotland Coronary Prevention Study Group (WOSCOPS). Influence of pravastatin and plasma lipids on clinical events in the west of scotland coronary prevention study. Circulation 97 (1998) 1440-1445
11. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 345 (1995) 1274-1275
12. Heart Protection Study Collaborative Group. Lancet 360 (2002) 7-22
13. Manninen V., Elo M.O., Frick M.H., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260 (1988) 641-651
14. Robins S.J., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: A randomized controlled trial. JAMA 285 (2001) 1585-1591
15. Tenkanen L., Manttari M., and Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 92 (1995) 1779-1785
16. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart risk in the Helsinki Heart Study: implications for treatment. Circulation 85 (1992) 37-45
17. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 102 (2000) 21-27
18. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the department of veterans affairs high-density lipoprotein intervention trial (VA-HIT). Arch Int Med 162 (2002) 2597-2604
19. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): a randomised controlled trial. Lancet 2005;366:1849-1861.
20. ACCORD. http://www.accordtrial.org/public/index.cfm (accessed 12 December, 2005).